INDIAN HEALTHCARE

Chill, trimmed pill prices won't hurt us

Donald Trump's executive order targeting international consumer price parity for prescription drugs in the US faces implementation challenges and potential legal battles. While unlikely to significantly impact Indian generic drug exporters, the order aims to increase imports from developed economies.

Apollo 24|7 forays into Insurance, plans to launch products from 12 insurers in two months

Apollo 24|7 is venturing into insurance with 'Apollo 24|7 Insurance Services,' a fully owned subsidiary, after securing regulatory approval as a corporate agent. The company plans to distribute Health, Life, and General Insurance products, targeting Rs 80 crore in revenue in the first year. Additionally, Apollo 24|7 will launch a health-first credit card and expand its 19-minute medicine delivery service.

Will these companies commit to ‘Make in India’? 8 MNC stocks with upside potential from just 7% to 70%

Imagine Apple did not have a manufacturing facility in India. It would have been in a very tight spot when Trump mega-tariffed China. Now, other MNCs with operations in China will also seek to derisk their supply chain. And India should be on top of the list. Of course, you can ask a pertinent question: Why, if the aim is to avoid tariff issues, do they not prefer the US? After all, that, according to President Trump, is the ultimate aim of the tariff war. However, the fact is that, even if these companies wanted to expand operations in the US, the cost (both of setting up and running operations) will be much higher than in India.

Revolutionary Non-Surgical Hair Growth Treatment by Dr. Stuti Khare Shukla - Consult Online Worldwide

Breakout Stocks: How to trade Redington, BSE and APL Apollo after fresh 52-week highs

The Indian market reversed Monday’s gains, with the Sensex dropping nearly 1,300 points and the Nifty slipping below 24,600. Despite the broader weakness, BSE, Redington, and APL Apollo hit fresh 52-week highs. Analysts see breakout opportunities in these stocks, citing strong volume trends and bullish price action, with defined upside targets and stop losses for the near term.

Stocks in news: HAL, Eicher Motors, Airtel, Tata Motors, Cipla

Indian markets are expected to focus on companies like HAL and Eicher Motors. These companies will announce their Q4 results. Tata Motors reported a profit decline. However, Airtel saw a significant profit increase. Metropolis Healthcare's profit decreased, while Bharti Hexacom's profit increased. Tata Steel plans a major capital expenditure. LIC increased its stake in Bank of India.

Renesas-CG Power venture likely to roll out first chip by mid-2026, says Hidetoshi Shibata

Japanese firm Renesas Electronics, which supplied components for Chandrayaan-3, expects its chip assembly venture with Murugappa group's CG Power to roll out its first chip by mid-2026. Mass production is slated for 2027 in Sanand. Renesas is also working on collaboration with other Indian partners and expanding its Bengaluru and Noida centres.

Hunt for R&D talent picks up pace at health-tech, pharma firms

Pharmaceutical and health-tech companies are significantly expanding their research and development teams to foster innovation and meet stringent regulatory standards. This surge is fueled by private equity investments and a growing emphasis on AI, machine learning, and digital therapeutics. Recruitment firms report a substantial increase in R&D hiring across various levels, with specialized talent in high demand.

Trump order unlikely to impact domestic generic industry working on razor-thin profits

The US order to lower prescription drug prices is unlikely to impact Indian generic drugmakers, as they already operate on low margins, experts say. The move mainly affects innovator pharma companies required to align prices with global benchmarks.

India’s safe-haven edge at risk, says CLSA, as Nifty and Sensex recoil after best day in 4 years

CLSA observed that India has emerged as a relative outperformer and a "safe haven" for investors amid escalating global trade tensions and India-Pakistan border conflicts. "The increase in these risks positioned India as a hiding place, making it the second-best performing market since March," the brokerage noted.

Trump’s drug price order raises alarm bells for Indian pharma

President Trump's plan to lower US prescription drug prices by aligning them with other countries could impact Indian pharmaceutical companies, which heavily rely on the US market for revenue. While primarily targeting innovator drugmakers, the move may squeeze Indian generic firms, potentially leading to margin pressure and strategic adjustments.

Pharma stocks decline amid Trump’s prescription drug price cuts announcement

The Nifty Pharma Index ended 0.2% higher Monday after tumbling almost 2.4% earlier in the day in response to Trump's remarks. The Sensex and Nifty jumped nearly 4%-posting their biggest single-day gains in four years. Of the 20 stocks in Nifty Pharma, 13 gained and seven declined.

India-Pakistan tensions paused, not over: Should you do any tactical alignment in investment portfolios during border hostilities?

India-Pakistan tensions: The tensions between India and Pakistan have paused now. However, the recent tensions have taken a toll on the investment portfolios. Currently, the tensions have not escalated to a war level. However, what should be your strategy during border hostilities? Read on to know how you should manage your investment portfolios.

LIC MF's Sumit Bhatnagar bets on smart beta schemes as ETF inflows hit Rs 19,000 cr in April

Also, Smart Beta and Factor – Based ETFs that use investment factors such as value, momentum, or low volatility for index construction rather than traditional market capitalisation, are garnering investor attention as well.

This is cessation of military operations, not ceasefire: Former Army Chief General Naravane

General Manoj Mukund Naravane spoke about Operation Sindoor. He said it warned Pakistan against aggression. India's strikes targeted terrorist infrastructure. This led to talks between India and Pakistan. Naravane supports diplomacy over war. He highlighted the high costs of conflict. War causes financial and human suffering. He echoed Prime Minister Narendra Modi's view that war is not desirable.

FPI declined in April to Rs 42 billion from Rs 63 billion in March: IDBI Capital

Foreign portfolio investors (FPIs) recorded a net inflow of Rs 42.2 billion, witnessing a decline from Rs 62.71 billion in March, according to the data compiled by IDBI Capital.

India sees improvement in maternal, child health indicators, says 2021 SRS report

India has made remarkable strides in maternal and child health between 2014 and 2021, with significant declines in MMR, IMR, NMR, and U5MR. The nation's progress has surpassed global averages, achieving substantial reductions in mortality rates compared to worldwide figures from 1990 to 2023. Several states have already met Sustainable Development Goals for maternal and child health.

Health Ministry cancels all leaves amid India-Pakistan tensions

In response to an impending situation, the Health Ministry has cancelled all leaves for its officials, ensuring preparedness by reviewing emergency health systems and mobilizing resources like ambulances, medical supplies, and hospital beds.

ETtech Deals Digest: Startups raise $568 million this week, up six-fold on-year

Startups across seed, early, and late stages raised the funds through 23 deals, compared to 51 in the year-ago period.

India-Pakistan Tensions: Health Minister Reviews Emergency Preparedness and Medical Readiness

Amid India-Pakistan tensions, J P Nadda reviewed emergency medical preparedness. The ministry established a 24x7 control center. Hospitals are ensuring drug and blood availability. AIIMS New Delhi mobilized doctors and nurses. Mock drills occurred at major hospitals. Training modules for emergency healthcare are being rolled out. The Union Health Secretary held meetings for coordination.

PB Healthcare’s fundraise; Wanted: Visa fairness

Happy Thursday! PB Fintech’s healthcare subsidiary has raised a funding round led by General Catalyst. This and more in today’s ETtech Morning Dispatch.

India-UK FTA to push trade to $100 billion by 2030, says India Inc; FMCG, healthcare to gain

The India-UK Free Trade Agreement is set to boost trade. India Inc anticipates bilateral trade to reach $100 billion by 2030. The deal is expected to strengthen strategic ties. Sectors like FMCG and healthcare will likely benefit. Industry groups report their demands were largely met. Ficci highlights market access and social security considerations.

TPG to acquire 35% stake in SCHOTT Poonawalla from Serum Institute of India

TPG Growth is set to acquire a 35% stake in SCHOTT Poonawalla from Serum Institute of India, with Novo Holdings co-investing. This deal aims to bolster the drug containment firm's growth in India and globally. Serum Institute will retain a minority stake, while SCHOTT Pharma remains the controlling stakeholder, leveraging TPG's healthcare expertise.